CGM After Discharge From Hospital

Starting soon · Not applicable

Conditions studied: Type 2 Diabetes, Steroid-induced Diabetes

In brief

This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.

Key facts

Study ID

NCT07510386

Run by

Icahn School of Medicine at Mount Sinai

People needed

64

Starts

2026-09-30

Expected to finish

2026-11-01

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult 18 years or older.
• Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge.

You may not qualify if…

• Type 1 diabetes
• Plan for discharge to rehabilitation/skilled nursing/hospice facility
• Contra-indication to sensor placement
• Pregnancy

Where it is running

• Icahn School of Medicine at Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.